| Neumann, Franz-Josef |
EUROSHOCK, NCT03813134: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock |
|
|
| Recruiting | N/A | 428 | Europe | Percutaneous coronary intervention (PCI), Pharmacological Support, VA-ECMO, Veno-Arterial Extra Corporeal Membrane Oxygenation. | University of Leicester, European Commission, University of Glasgow, KU Leuven, University of East Anglia, Deutsches Herzzentrum Muenchen, A.O. Ospedale Papa Giovanni XXIII, Chalice Medical Ltd, Ludwig-Maximilians - University of Munich, University of Tromso, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Paula Stradina Liniska Universitates, Accelopment AG, Universiteit Antwerpen, Cardiovascular European Research Centre (CERC) | Cardiogenic Shock | 03/23 | 02/24 | | |
| Recruiting | N/A | 768 | Europe, RoW | Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site. | Meril Life Sciences Pvt. Ltd. | Aortic Valve Stenosis | 03/24 | 12/33 | | |
| Kim, Won Seog |
| Recruiting | 4 | 2426 | RoW | Treatment, Albumin and crystalloid, Placebo, Crystalloid only | Asan Medical Center, Samsung Medical Center, Gangnam Severance Hospital, Chungnam National University Hospital, Seoul National University Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Hanyang University, Korea University Ansan Hospital | Septic Shock | 09/25 | 12/25 | | |
PROTECT-HBR, NCT04416581: Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy |
|
|
| Recruiting | 4 | 3100 | RoW | PPI, P-CAB 50 | Duk-Woo Park, MD | Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction | 09/26 | 12/27 | | |
| Active, not recruiting | 3 | 197 | RoW | besifovir 150mg, tenofovir 300mg | IlDong Pharmaceutical Co Ltd | Chronic Hepatitis B | 02/16 | 01/23 | | |
| Recruiting | 3 | 302 | RoW | Amiodarone Injection | Won Young Kim | Cardiac Arrest, Ventricular Arrythmia | 02/23 | 02/23 | | |
NCT05450601: A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients |
|
|
| Completed | 3 | 249 | RoW | HCP2102-1, HPP2104-1, HCP2102-2, HPP2104-2, RLD2106-1, HPP2103-1, RLD2106-2, HPP2103-2 | Hanmi Pharmaceutical Company Limited | Hypertension | 12/23 | 12/23 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Active, not recruiting | 3 | 941 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age with Partial-onset (focal) Seizures |
|
|
| Recruiting | 3 | 140 | Europe, US, RoW | Xcopri | SK Life Science, Inc. | Partial Epilepsy | 05/26 | 07/26 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 06/25 | 01/28 | | |
| Completed | 2 | 108 | Europe, US, RoW | AFM13 | Affimed GmbH | Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides | 05/22 | 01/24 | | |
NCT02445404: Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL |
|
|
| Recruiting | 2 | 134 | RoW | CHOP, cyclophosphamide, cyclophosphamide, vincristine,prednisone, fractionated ICED, ifosfamide, carboplatin, etoposide, dexamethasone | Samsung Medical Center | Peripheral T-cell Lymphoma | 06/22 | 06/23 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type |
|
|
| Active, not recruiting | 2 | 23 | RoW | IMC-001, Not confirm yet | ImmuneOncia Therapeutics Inc. | Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma | 07/24 | 02/26 | | |
NCT04921189: Steroid, Thiamine and Ascorbic Acid for Comatose Out-of-hospital Cardiac Arrest Survivors |
|
|
| Recruiting | 2 | 160 | RoW | The combined supplement of Ascorbic acid, Thiamine, and Cortisol, Ascorbic acid, Thiamine hcl, Cortisolu, Placebo, Normal saline | Asan Medical Center, Seoul St. Mary's Hospital, Wonju Severance Christian Hospital, Samsung Changwon Hospital, Samsung Medical Center, Chung-Ang University, Hanyang University, Ewha Womans University, Hanil General Hospital | Out-Of-Hospital Cardiac Arrest, Postcardiac Arrest Syndrome | 11/24 | 11/25 | | |
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease |
|
|
| Not yet recruiting | 2 | 393 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Liver Diseases, Alcoholic | 12/26 | 03/27 | | |
Lemon-C, NCT04627753: Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. |
|
|
| Recruiting | 2 | 30 | RoW | Rituximab, lenalidomide, Truxima Inj, Lenalid | Kim, Seok Jin, Celltrion, Samyang Biopharmaceuticals Corporation | Primary CNS Lymphoma | 11/25 | 11/26 | | |
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) |
|
|
| Recruiting | 2 | 280 | Europe, Canada, Japan, US, RoW | Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo | GlaxoSmithKline | Chronic Hepatitis B Virus Infection, Hepatitis B | 10/27 | 10/27 | | |
| Recruiting | 2 | 33 | RoW | R2P -> RP | NOBO Medicine | Primary CNS Lymphoma (PCNSL) | 06/26 | 12/27 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 07/27 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
| Active, not recruiting | 2 | 81 | Europe, RoW | Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma | Nordic Lymphoma Group, AstraZeneca | MCL, Mantle Cell Lymphoma | 01/27 | 01/27 | | |
NCT03789617: A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies |
|
|
| Recruiting | 1/2 | 72 | RoW | EBViNT Cell, Eutil autologous blood-derived T lymphocytes | Eutilex | EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma | 09/22 | 12/24 | | |
| Active, not recruiting | 1/2 | 323 | US, RoW | FLX475, pembrolizumab (KEYTRUDA®) | RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC | Advanced Cancer | 09/24 | 01/25 | | |
SIENA, NCT06552559: Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1/2 | 37 | RoW | Selinexor, Ifosfamide, carboplatin, etoposide, dexamethasone | Samsung Medical Center, Korean Society of Hematology | B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, CNS Metastases | 12/26 | 12/27 | | |
NCT02580617: A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease |
|
|
| Recruiting | 1 | 9 | RoW | ALLO-ASC, ALLO-ASC-CD | Anterogen Co., Ltd. | Crohn's Disease | 12/23 | 12/23 | | |
NCT04903314: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures |
|
|
| Recruiting | 1 | 24 | US, RoW | Xcopri | SK Life Science, Inc. | Partial Epilepsy | 10/25 | 03/26 | | |
NCT06699771: Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies |
|
|
| Not yet recruiting | 1 | 48 | RoW | GCC2005, Cyclophosphamide, Fludarabine | GC Cell Corporation, Artiva Biotherapeutics, Inc. | Lymphoma, T-Cell | 04/26 | 08/27 | | |
NCT06522815: Updating Deep Learning Algorithms for OSA Monitoring |
|
|
| Recruiting | N/A | 107 | RoW | CART-I plus, Polysomnography | Sky Labs, Gangnam Severance Hospital | Obstructive Sleep Apnea, Obstructive Sleep Apnea-hypopnea | 04/25 | 07/25 | | |
NCT02031913: Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD |
|
|
| Completed | N/A | 500 | RoW | | Seoul National University Boramae Hospital | Chronic Hepatitis B, Hepatic Fibrosis, Fatty Liver | 11/22 | 12/22 | | |
NCT05386953: Intraoperative Normal Saline Administration and Acute Kidney Injury in Patients Undergoing Liver Transplantation |
|
|
| Recruiting | N/A | 1440 | RoW | Normal saline, Balanced crystalloid solution, Lactated Ringer's solution, Plasma solution | Seoul National University Hospital | End Stage Liver DIsease, Liver Transplant; Complications, Liver Cirrhosis | 12/22 | 12/22 | | |
NCT05457114: Association Between the Use of Pulmonary Artery Catheter and Clinical Outcomes After Liver Transplantation |
|
|
| Recruiting | N/A | 1970 | RoW | Pulmonary artery catheter (Edward Lifesciences, Irvine, California, USA), FloTrac Vigileo system (EV1000 clinical platform, Edward Lifesciences, Irvine, California, USA) | Seoul National University Hospital | End Stage Liver DIsease, Liver Transplant; Complications, Liver Cirrhosis, Liver Diseases | 12/22 | 12/22 | | |
NCT03117036: Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III |
|
|
| Recruiting | N/A | 600 | RoW | Chemotherapy, Treatment | Samsung Medical Center, Samsung Genomic Institute | Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin | 12/24 | 12/26 | | |
NCT02206841: Establishment of NAFLD Cohort and Development of Fibrosis Markers |
|
|
| Recruiting | N/A | 1000 | RoW | Liver biopsy, ARFI, SWE, Transient elastography | Seoul National University Boramae Hospital | Fibrosis of Liver | 12/29 | 12/30 | | |
| Recruiting | N/A | 81 | RoW | Steroids, Dexamethasone, Etoposide | Samsung Medical Center | Hemophagocytic Lymphohistiocytoses | 12/25 | 12/26 | | |
| Recruiting | N/A | 768 | Europe, RoW | Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site. | Meril Life Sciences Pvt. Ltd. | Aortic Valve Stenosis | 03/24 | 12/33 | | |
AIM-CMRA, NCT05473117: iNav-based, Automated Coronary Magnetic Resonance Angiography for the Detection of Coronary Artery Stenosis |
|
|
| Not yet recruiting | N/A | 160 | Europe | Coronary Magnetic Resonance Angiography (CMRA) | Aarhus University Hospital | Coronary Artery Stenosis | 12/25 | 12/26 | | |
NCT05124912: REMASTer: REcurrent Brain Metastases After SRS Trial |
|
|
| Recruiting | N/A | 261 | US | Radiation Therapy, Steroid Therapy, Laser Interstitial Thermal Therapy | Monteris Medical | Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases | 12/26 | 10/28 | | |
NCT03183661: A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial |
|
|
| Recruiting | N/A | 9 | RoW | ALLO-ASC-CD, Allogenic adipose-derived mesenchymal stem cell | Anterogen Co., Ltd. | Crohn Disease | 12/26 | 12/26 | | |
NCT04615091: Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery |
|
|
| Recruiting | N/A | 250 | Europe, Canada, US, RoW | | Azienda Ospedaliera Universitaria Integrata Verona | Advanced Chronic Liver Disease, Surgery--Complications | 10/21 | 08/22 | | |
ATLAS TAVI, NCT04914481: Anatomic Stenosis Severity as a Prognostic Marker in Patients With Low-Flow Low-Gradient Aortic Stenosis Undergoing TAVI |
|
|
| Recruiting | N/A | 1500 | Europe, Canada, RoW | | Universitätsklinikum Hamburg-Eppendorf, Institut universitaire de cardiologie et de pneumologie de Québec | Low-Flow, Low-Gradient Aortic Stenosis | 12/22 | 12/25 | | |
